WaVe Life Sciences IPO

11/11/2015

IPO

$102,400,000

We intend to use the net proceeds from this offering as follows: approximately $11.3 million to fund additional preclinical studies and Phase 1 clinical trials for our HD HTT SNP-1 program; approximately $13.4 million to fund the selection of a lead product candidate and additional preclinical studies and Phase 1 clinical trials for our HD HTT SNP-2 program; approximately $14.2 million to fund additional preclinical studies and Phase 1 clinical trials for our DMD Exon 51 program; and approximately $11.6 million to fund the selection of a lead product candidate and additional preclinical studies and Phase 1 clinical trials for our IBD SMAD7 program. The remainder of the net proceeds will be used to advance our discovery programs, to expand our pipeline, for working capital and for other general corporate purposes. We may also use a portion of the net proceeds to acquire, license and invest in complementary products, technologies or businesses; however, we currently have no agreements or

Publicly-held

Biopharmaceutical

733 Concord Ave.
Cambridge, MA 02138
USA

WaVe Life Sciences (NASDAQ: WVE) is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.